Pathogenic mechanisms

A01		INVESTIGATING THE EFFECT OF DNA MAINTENANCE GENES IN DROSOPHILA MELANOGASTER MODEL…
A02		STRIATAL PROCEDURAL MEMORY-INDUCED TRANSCRIPTOME AND EPIGENOME ARE SEVERELY IMPAIR…
A03		PRECISE MACHINE-LEARNING SUGGESTS THAT NEURONAL DEATH IN HD IS MAINLY DRIVEN BY TH…
A04		CIRCHTT, A CIRCULAR RNA FROM THE HUNTINGTON’S DISEASE GENE LOCUS: FUNCTIONAL CHARA…
A05		EFFECT OF SMALL MOLECULE INHIBITORS ON THE AGGREGATION MECHANISM OF MUTANT HUNTING…
A06		TUNING THE STRESS RESPONSE PATHWAY TO RESPOND TO POLYQ AGGREGATION…
A07		HUNTINGTIN-DEPENDENT STABILITY OF HAP40 AND DECREASED HAP40 LEVELS IN HUNTINGTON’S…
A08		SYNAPTIC VESICLE RECYCLING IS DISRUPTED IN A MOUSE MODEL OF HUNTINGTON’S DISEASE…
A09		ADAM10 ACTIVITY AT THE HUNTINGTON’S DISEASE PRESYNAPSE…
A10		NAPDH OXIDASES (NOXS) EXOCYTOSIS AND ITS RELEVANCE IN HUNTINGTON’S DISEASE (HD) PA…
A11		HUNTINGTIN-MEDIATED AXONAL TRANSPORT REQUIRES ARGININE METHYLATION BY PRMT6…
A12		IDENTIFICATION OF THE KEY ROLE OF WHITE MATTER IN THE PATHOGENESIS OF HUNTINGTON’S…
A13		ABNORMAL SPINAL CORD MYELINATION DUE TO OLIGODENDROCYTE DYSFUNCTION IN A MODEL OF…
A14		RETINAL AND STRIATAL PROFILING OF THE R6/1 MOUSE MODEL OF HUNTINGTON’S DISEASE…
A15		HYPOTHALAMIC EXPRESSION OF HUNTINGTIN CAUSES DISTINCT METABOLIC CHANGES IN THE R6/…
A16		UNDERSTANDING THE ASSOCIATION BETWEEN MITOCHONDRIAL DNA COPY NUMBER AND TELOMERE L…
A17		TARGETING MITOPHAGY IN HUNTINGTON’S DISEASE PATIENTS’ FIBROBLASTS…
A18		CAN CUMULATION OF NEURODEGENERATIVE DISORDERS SIGNIFICANTLY PROMOTE MITOCHONDRIAL…
A19		HIGH-RESOLUTION RESPIROMETRY AS A TOOL TO ASSESS SKELETAL MUSCLE MITOCHONDRIAL STA…
A20		ASSESSMENT OF MUSCLE REGENERATION IN THE R6/2 MOUSE MODEL OF HUNTINGTON’S DISEASE…
A21		ASSESSMENT OF SATELLITE PROGENITOR CELL DIFFERENTIATION IN HD SKELETAL MUSCLE IN V…

Models for HD

B01		IN VITRO STUDY OF NEURODEVELOPMENT IN HUNTINGTON’S DISEASE…
B02		A NEW IN VIVO AND IN VITRO SINGLE-CELL ATLAS OF DEVELOPING MEDIUM SPINY NEURONS TO…
B03		NOVEL HD MOUSE MODELS ENABLING NEW PATHOGENIC MECHANISMS DISCOVERY…
B04		IDENTIFICATION OF THE NEURAL CORRELATES UNDERLYING CONFLICT RESOLUTION IN THE RODE…

Genetic modifiers

C01		THE EFFECT OF MISMATCH REPAIR PROTEINS IN A HUNTINGTON’S DISEASE CELLULAR MODEL…
C02		FAN1 CONTROLS CAG REPEAT EXPANSION IN HUNTINGTON’S DISEASE BY DUAL FUNCTIONS, MLH1…
C03		FAN1 PREVENTS CRISPR-CAS9 NICKASE-INDUCED CONTRACTIONS OF CAG/CTG REPEATS…
C04		PROTEIN CODING TANDEM REPEAT IN TCERG1 MODIFIES HUNTINGTON’S DISEASE ONSET…
C05		SAPAP3 SCAFFOLDING PROTEIN AS A REGULATOR OF MITOCHONDRIAL FUNCTION IN HUNTINGTON’…
C06		COMPARISON OF MODELS FOR ESTIMATING AGE AT MOTOR ONSET IN HD…
C07		GENETIC RISK FOR PSYCHIATRIC DISORDERS IS ASSOCIATED WITH PSYCHIATRIC AND COGNITIV…

Wet biomarkers

D01		TWO INDEPENDENT VALIDATIONS OF A MUTANT HUNTINGTIN PROTEIN (MHTT) ASSAY TO SUPPORT…
D02		CEREBROSPINAL FLUID AMYLOID BETA AND GLIAL FIBRILLARY ACIDIC PROTEIN CONCENTRATION…
D03		CIRCULAR RNAS AS POTENTIAL BIOMARKERS IN HUNTINGTON’S DISEASE PATHOGENESIS…
D04		BLOOD GLUCOSE AND INSULIN LEVELS FOLLOWING AN ORAL GLUCOSE CHALLENGE ARE PROMISING…

Imaging

E01		WIDESPREAD LOSS OF PRESYNAPTIC TERMINAL MARKER SV2A IN EARLY HUNTINGTON DISEASE…
E02		LONGITUDINAL HYBRID PET/MRI IN JUVENILE-ONSET HUNTINGTON DISEASE (JOHD)…
E03		UNCOVERING THE TEMPORAL SEQUENCE OF REGIONAL BRAIN VOLUME AND NEURAL CONNECTIVITY…
E04		FRONTO-STRIATAL CIRCUITS FOR COGNITIVE FLEXIBILITY IN FAR FROM ONSET HUNTINGTON’S…
E05		MUTATION-RELATED APPARENT MYELIN, NOT AXON DENSITY, DRIVES WHITE MATTER PATHOLOGY…
E06		DRUMMING MOTOR SEQUENCE TRAINING INDUCES APPARENT MYELIN REMODELLING IN HUNTINGTON…
E07		ALTERED IRON AND MYELIN IN PREMANIFEST HUNTINGTON’S DISEASE MORE THAN 20 YEARS BEF…
E08		TRACKING THE NEURODEGENERATION PATTERN OF THE ANTERIOR THALAMIC RADIATIONS IN HD:…
E09		MAGNETIC RESONANCE IMAGING VISUAL ANALYSIS OF NEUROMELANIN AND NIGROSOME-1 FOR THE…

Clinical studies

F01		DEVELOPMENT OF THE HUNTINGTON’S DISEASE INTEGRATED STAGING SYSTEM (HD-ISS)…
F02		MODELLING HUNTINGTON’S DISEASE PROGRESSION: INTERPRETATION, STAGING AND PROGNOSIS…
F03		FINE-GRAINED PREDICTION OF HUNTINGTON’S DISEASE PROGRESSION USING A STACKED ENSEMB…
F04		LINEAR MIXED MODEL FOR THE AGE OF ONSET PREDICTION IN HUNTINGTON DISEASE FROM A PE…
F05		BIOLOGICAL AND CLINICAL CHARACTERISTICS OF GENE CARRIERS FAR FROM PREDICTED ONSET…
F06		‘WHERE DO WE GO FROM HERE?’: A META-SYNTHESIS OF QUALITATIVE LITERATURE EXAMINING…
F07		DEMOGRAPHIC CHARACTERISTICS AND HEALTH RESOURCE USE OF THE EUROPEAN PARTICIPANTS F…
F08		HUNTINGTON’S DISEASE BURDEN OF ILLNESS (HDBOI): STUDY METHODOLOGY, SAMPLE REPRESEN…
F09		LATE ONSET HUNTINGTON’S DISEASE PHENOTYPE PROGRESSION. 2 YEARS FOLLOW-UP IN 220 PA…
F10		DEVELOPMENT OF ASSESSMENTS FOR LATER STAGE HUNTINGTON’S DISEASE: HD STRUCTURED INT…
F11		IMPACT ON THE GRANDPARENTS-GRANDCHILDREN RELATIONSHIP IN HUNTINGTON’S DISEASE…
F12		RESEARCH PARTICIPATION: THE VIEW OF PERSONS AT RISK AND PERSONS WITH PREMANIFEST H…
F14		COLLABORATING WITH THE COMMUNITY TO CONDUCT CLINICAL TRIALS IN HUNTINGTON’S DISEAS…
F15		VISUAL-COGNITIVE IMPAIRMENT IN ASYMPTOMATIC AND SYMPTOMATIC CARRIERS OF HUNTINGTON…
F16		ETHNOGRAPHY AND SOCIAL COGNITION…
F17		AN ETHNOGRAPHIC PROTOCOL FOR EXPLORING SOCIAL FUNCTION DURING A PANDEMIC…
F18		THE ETHICS OF EXPLORING SOCIAL COGNITION IN HD USING ETHNOGRAPHY DURING A PANDEMIC…
F19		COGNITIVE RESERVE: THE LEISURE TIME CONCURS TO THE COGNITION PERFORMANCE AND TO TH…
F20		IS BURNOUT AN EARLY SIGN OF HUNTINGTON’S DISEASE AND MORE PREVALENT THAN IN THE GE…
F21		ON THE ASSOCIATION BETWEEN APATHY AND DEFICITS OF SOCIAL COGNITION AND EXECUTIVE F…
F22		NOVEL MEASURES OF APATHY IN HUNTINGTON’S DISEASE: CROSS-SECTIONAL AND LONGITUDINAL…
F23		IMPULSIVITY AND IRRITABILITY IN HUNTINGTON’S DISEASE: A COMMON FOUNDATION?…
F24		UNSUPERVISED CLUSTERING REVEALS LONGITUDINAL PSYCHIATRIC SIGNATURES IN HD…
F25		THE CLINICAL, IMAGING AND BIOLOGICAL FEATURES OF PSYCHOSIS IN HAN CHINESE PATIENTS…
F26		IDENTICAL TWINS .. ARE THEY IDENTICAL?…
F27		CLINICAL PRESENTATIONS IN PATIENT WITH 34 CAG-REPEATS (CASE REPORT)…
F28		NOVEL MUTATIONS AND FINDINGS IN A COHORT OF MCLEOD NEUROACANTHOCYTOSIS, AN X-LINKE…
F29		DOMINO-HD: A 12-MONTH OBSERVATIONAL COHORT STUDY OF LIFESTYLE FACTORS IN PEOPLE WI…
F30		Q-MOTOR ASSESSMENTS IN THE BIDIRECT COHORT STUDY: FEASIBILITY, NORMATIVE DATA AND…
F31		EXAMINING THE EFFECT OF EXERCISE ON THE PROGRESSION AND SEVERITY OF HUNTINGTON’S D…
F32		EXPLORING THE FEASIBILITY OF A NOVEL AND EFFICIENT TRIAL DESIGN FOR THE EVALUATION…
F33		PERCEPTIONS, MOTIVATORS AND BARRIERS TO THE ACCEPTANCE OF WEARABLE ACTIVITY TRACKE…
F34		REMOTE MONITORING OF SPEECH IN HD USING MOBILE DEVICES…
F35		SLEEP MONITORING IN HUNTINGTON’S DISEASE USING FITBIT COMPARED TO POLYSOMNOGRAPHY….
F36		DXA, BIA, ANTHROPOMETRY AND SKIN FOLDS METHODOLOGY IN BODY COMPOSITION…
F38		SKILL-BASED DYSPHAGIA TRAINING AS AN INTERVENTION FOR INDIVIDUALS WITH HUNTINGTON’…
F39		DESIGN OF AN ADAPTIVE RANDOMIZED CONTROLLED PHASE 1B/2A TRIAL OF WVE-003 IN PARTIC…
F40		PROOF-OF-CONCEPT STUDY TESTING SOM3355, A VMAT2 INHIBITOR FOR THE TREATMENT OF CHO…
F41		THE PROOF-HD PHASE 3 STUDY: PRIDOPIDINE’S OUTCOME ON FUNCTION IN HUNTINGTON DISEAS…
F42		EXPOSURE RESPONSE ANALYSIS (PKPD) PREDICTS OPTIMAL EXPOSURE OF PRIDOPIDINE FOR CLI…
F43		PRIDOPIDINE MAINTENANCE OF TOTAL FUNCTIONAL CAPACITY (TFC) CORRELATES WITH STABILI…
F44		HUNTINGTON’S DISEASE PATIENTS AND FAMILIES FACING COVID-19 EMERGENCY IN ITALY…
F45		IMPACT OF COVID-19 PANDEMIC IN PATIENTS WITH HUNTINGTON DIESEASE…
F46		THE EUROPEAN HUNTINGTON’S DISEASE NETWORK…
F47		THE EUROPEAN HUNTINGTON’S DISEASE NETWORK (EHDN) SCIENTIFIC SUPPORT…
F48		ENROLL-HD STUDY STATUS…
F49		ENROLL-HD CLINICAL TRIAL COMMITTEE…
F50		ENROLL-HD PLATFORM SUPPORT FOR INDUSTRY AND ACADEMIC SPONSORS…
F51		ENROLL-HD PLATFORM DATA RESOURCES…
F52		ENROLL-HD PLATFORM BIOSAMPLE RESOURCES…
F53		INTRODUCING JOIN-HD: THE JUVENILE ONSET INITIATIVE FOR HUNTINGTON’S DISEASE…
F54		“SPAZIO HUNTINGTON – A PLACE FOR CHILDREN”: AN ITALIAN OBSERVATIONAL, MULTICENTRE,…

Genetic testing and counselling

G01		MOLECULAR TESTING FOR HUNTINGTON DISEASE AND THE RISK OF DISCLOSURE OF UNSOLICITED…
G02		THE EXPERIENCE OF LIVING IN THE PRE-MANIFEST STAGE OF HUNTINGTON’S DISEASE: AN INT…
G03		THE HOLD ME TIGHT RELATIONSHIP PROGRAM FOR COUPLES FACING HUNTINGTON’S DISEASE…

Clinical care and clinical services

H01		DISEASE BURDEN IN PATIENTS WITH HUNTINGTON’S DISEASE FROM A NATIONWIDE SWEDISH REG…
H02		‘THERE IS THIS BIG GAP’: THE UNMET NEEDS OF PEOPLE WITH ADVANCED HD, FAMILIES AND…
H03		EXPERIENCES OF OUTPATIENTS WITH HUNTINGTON’S DISEASE WITH CASE MANAGEMENT; A QUALI…
H04		MAPPING HD SERVICES IN THE UK – A PARTNERSHIP APPROACH…
H05		A JOINT INITIATIVE FOR IMPROVED CARE OF HUNTINGTON’S DISEASE PATIENTS IN GERMANY…
H06		CHALLENGES AND OPPORTUNITIES OF HUNTINGTON’S DISEASE IN EGYPT: A QUALITATIVE STUD…
H07		THE IMPACT OF A HIGH CARE UNIT FOR PATIENTS WITH HUNTINGTON’S DISEASE FROM A MULTI…
H08		MULTIDISCIPLINARY TREATMENT AND CARE WORKING GROUP — OCCUPATIONAL THERAPY…
H09		BEST PRACTICE OCCUPATIONAL THERAPY FOR PEOPLE WITH HD…
H10		APPLICABILITY AND EFFECTS ON INITIATIVE OF SOCIAL ROBOT TESSA IN PATIENTS WITH HUN…
H11		IMPLEMENTING PHYSIOTHERAPY HUNTINGTON’S DISEASE GUIDELINES IN CLINICAL PRACTICE: A…
H12		PSYCHOLOGICAL INTERVENTIONS FOR PEOPLE WITH HUNTINGTON’S DISEASE: A CALL TO ARMS…
H13		ADVANCE EUTHANASIA DIRECTIVES IN HUNTINGTON’S DISEASE: A PATIENTS’ PERSPECTIVE…
H14		END-OF-LIFE CONVERSTATIONS WITH PATIENTS WITH HUNTINGTON’S DISEASE…

Experimental therapeutics — preclinical

I01		ORALLY BIOAVAILABLE SMALL MOLECULE SPLICING MODIFIERS WITH SYSTEMIC AND EVEN HTT-L…
I02		A CAG REPEAT-TARGETING ARTIFICIAL MIRNA LOWERS THE MUTANT HUNTINGTIN LEVEL IN THE…
I03		CPEB ALTERATION AND ABERRANT TRANSCRIPTOME-POLYADENYLATION UNVEIL A TREATABLE VITA…
I04		REDUCTION OF GLUTAMATE DEHYDROGENASE INCREASES AUTOPHAGY AND AMELIORATE MOTILITY A…
I05		INCREASING BRAIN PALMITOYLATION RESCUES BEHAVIOR AND NEUROPATHOLOGY IN HUNTINGTON…
I06		SREBP2 DELIVERY TO STRIATAL ASTROCYTES NORMALIZES TRANSCRIPTION OF CHOLESTEROL BIO…
I07		A NEW GENERATION OF BRAIN-TARGETED NANOPARTICLES FOR CHOLESTEROL DELIVERY IN HUNTI…
I08		LXR SIGNALING IN THE STRIATUM AND NEUROPROTECTION IN HUNTINGTON’S DISEASE…
I09		IN VIVO MTHTT PROTEIN REDUCTION IN THE CNS AND PERIPHERY BY PASSIVE IMMUNIZATION W…
I10		ACUTE INNATE IMMUNE RESPONSES TO SIMULATED TRANSPLANTATION SURGERY IN TWO HD MOUSE…
I11		PHARMACOLOGIC INHIBITION OF THE CLASSICAL COMPLEMENT PATHWAY ENHANCES NEURONAL FUN…
I12		DECIPHERING THE NEUROPROTECTIVE ROLE OF SIGMA1 RECEPTOR, AN IMPORTANT FUNCTION TO…
I13		PRIDOPIDINE RESTORES MITOCHONDRIAL FUNCTION AND DECREASES ER STRESS WHICH IS MEDIA…

Clinical therapeutics

J01		TRIHEPTANOIN IS ASSOCIATED WITH CLINICAL STABILITY AND DECREASED CAUDATE ATROPHY I…
J02		TRIDENT: INVESTIGATING THE SAFETY ANF FEASIBILITY OF FETAL CELL TRANSPLANTS IN HUN…
J03		CLINICAL TRANSLATION OF STEM CELL THERAPIES FOR HUNTINGTON’S DISEASE (HD)…
J04		EFFICACY AND SAFETY OF TIAPRIDE FOR CHOREA TREATMENT IN HUNTINGTON’S DISEASE: A SY…
J05		A DIFFERENT DEPRESSION: ANTIDEPRESSANT EFFICACY AND COGNITIVE MECHANISMS OF MOOD D…